Unknown Manufacturer
Orally administered bradykinin B2 receptor antagonist under development by Pharvaris N.V. for hereditary angioedema (HAE). In the pivotal Phase 3 CHAPTER-3 study, once-daily deucrictibant extended-release (XR) 40 mg reduced monthly HAE attack rates by 83% versus placebo (p<0.0001); a prophylaxis New Drug Application submission is planned for the first half of 2027.
Orally administered bradykinin B2 receptor antagonist under development by Pharvaris N.V. for hereditary angioedema (HAE). In the pivotal Phase 3 CHAPTER-3 study, once-daily deucrictibant extended-release (XR) 40 mg reduced monthly HAE attack rates by 83% versus placebo (p<0.0001); a prophylaxis New Drug Application submission is planned for the first half of 2027.
Bradykinin B2 receptor antagonist. Deucrictibant blocks the bradykinin B2 receptor, the downstream effector of vascular permeability that drives swelling attacks regardless of which upstream pathway generates bradykinin.
1 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
